Lana Pine

Of the 135 laser flare photometry readings to identify uveitis among patients with juvenile idiopathic arthritis, only 3% were characterized as a false positive.

Patients with inflammatory arthritis demonstrated significantly increased odds of depression and anxiety health care encounters and use of anxiolytics and antidepressants.

Lora Black, PhD, sheds light on the importance of patient-centered education and comprehensive care in fibromyalgia.

The presence of mental health, pain-related illnesses, and metabolic diseases were significantly associated with the worsening of arthritis-related pain, severity, and disease activity.

Angus Worthing, MD, discusses the recent developments in rheumatology and his predictions for the future of treatment moving into 2024 and beyond.

Findings shed light on the potential significance of recognizing and managing type D personality traits in the context of fibromyalgia care.

Proactive disease management could result in more positive emotional and mental experiences in patients with gout.

After adjusting for confounders, data revealed higher levels of obesity indices were linked with a gradual and dose-dependent increase in urate levels.

Findings revealed an elevation of educational attainment by one standard deviation exhibited a protective effect against gout.

Thematic analysis revealed common themes, including uncertainty about the cause of fibromyalgia, feelings of invisibility, confusion about symptoms and flares, and a strong desire for more accessible treatment information.

Gout incidence rate significantly increased after relieving urinary tract obstruction.

Wesley Mizutani, MD, discusses California's SB 496 legislation, which addresses the crucial role of biomarkers in guiding optimal drug selection to improve overall healthcare outcomes.

There were no differences in patient-rated pain scores, time to flare resolution, and the risk of recurrent flare in patients initiating urate-lowering therapy during treatment and those delaying treatment.

Roger A Levy, MD, PhD, discusses the transformative impact of the KDIGO guidelines, which recommend early initiation of belimumab for lupus nephritis.

Roger A Levy, MD, PhD, discusses the recent guideline updates regarding the treatment and management of lupus nephritis.

Results showed no differences regarding safety, although the biosimilar group had slightly more discontinuations due to inefficacy.

Improvements in insulin resistance were reported in patients with RA and type 2 diabetes treated with tofacitinib.

Benign prostatic hyperplasia was 1.13-fold higher in those with gout when compared with controls.

Patients with gout had a 1.26-fold higher likelihood of experiencing migraines when compared with those without gout.

A study compared the efficacy of febuxostat and benzbromarone in treating gout, emphasizing the lack of consensus in previous research and the need for future, well-designed studies.

Compared to routine care, TCMD could better reduce the incidence of adverse events and the level of laboratory indicators.

Significant differences in the practice of primary healthcare physicians were observed based on medical specialty when treating and managing asymptomatic hyperuricemia and gout.

Only 10% of providers surveyed follow the American College of Rheumatology criteria for fibromyalgia.

Entering menopause prior to age 45 was associated with a 46% increased risk of developing RA compared with those who began menopause at ≥50 years.

Results indicate the potential relevance of pressure pain thresholds for understanding the mechanisms that contribute to pain in fibromyalgia.

Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.

Results indicated patients with GERD are at a 69% increased risk of developing RA.

The PETRA questionnaire proves valuable in assessing the transition readiness of juvenile idiopathic arthritis patients into adult care, with a focus on self-management skills.

The rheumatology month in review highlights fibromyalgia complexities, lupus advancements, and dietary links to gout for improved management.

BLA submission was based on data from phase 3 clinical trials in which DMB-3115 showed no clinically meaningful differences compared with the reference product for the treatment of plaque psoriasis.